Apolipoprotein-AI-containing particles and atherosclerosis.
Fruchart
J C
JC
SERLIA, Institute Pasteur, Lille, France.
Castro
G
G
Duriez
P
P
D000818:Animals; D030801:Animals, Genetically Modified; D016632:Apolipoprotein A-I / Q000378:metabolism*; D016633:Apolipoprotein A-II / Q000378:metabolism; D001161:Arteriosclerosis / Q000378:metabolism*; D003324:Coronary Artery Disease / Q000378:metabolism; D004041:Dietary Fats / Q000494:pharmacology; D006801:Humans; D006951:Hyperlipoproteinemias / Q000378:metabolism; D000960:Hypolipidemic Agents / Q000494:pharmacology; D008136:Longevity
D016632:Apolipoprotein A-I; D016633:Apolipoprotein A-II; D004041:Dietary Fats; D000960:Hypolipidemic Agents